Sirtex Medical Limited, REA Group, Reject Shop, Magellan Financial: Should you buy?

Is it too late or could there still be upside potential in these four stocks?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The rallying S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) sent a number of stocks higher on Friday with Sirtex Medical Limited (ASX: SRX), REA Group Limited (ASX: REA), Reject Shop Ltd (ASX: TRS) and Magellan Financial Group Ltd (ASX: MFG) all gaining around 4% or more.

The rally has caught some investors off-guard and has them questioning whether they need to be investing more to maximise their upside.

Sirtex

Sirtex’s share price has hit a new record high of $19 and comes in the wake of this week’s announcement by the company that dose sales of its targeted radiation therapy for liver cancer grew 27.1% during the fourth quarter. Sirtex continues to report outstanding results and has now posted 40 consecutive quarters of dose sales growth. So while its all-time high share price looks expensive, the superb growth of the company arguably justifies the current price.

REA Group

REA’s shares are gaining ground again after getting the wobbles in the face of a reported “uprising” from real estate agents. With a new service partnership program announced at the start of the month it appears any issues have been smoothed over. As the leading online portal for real estate classifieds, REA has a commanding position that appears to be unshakeable.

Reject Shop

Unlike Sirtex and REA, Reject Shop is far from riding high. The stock has been slammed in the past six months, having lost 44% of its price. It looks like the worst of the share price falls are now well and truly behind the discount retailer, with investors who picked the bottom already up 20%.

Magellan Financial

The recent weakness in global fund manager Magellan’s share price may have created a buying opportunity for investors who remain bullish on the outlook for equity markets in general and Magellan’s growth profile specifically. After reaching a high of $14.38 in April the stock’s price has fallen away to the mid-$11 range. Although the stock trades on a relatively high multiple this could well be justified given the group’s leverage to higher funds under management and its growth outlook.

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »